COMMUNIQUÉS West-GlobeNewswire

Larkspur Biosciences Begins Dosing in Clinical Study of LRK-4189, a First-in-Class Targeted Protein Degrader
03/12/2025
LRK-4189, which targets PIP4K2C, a key cancer cell fitness target, is being developed for microsatellite stable (MSS) colorectal cancer (CRC) and other solid tumors Clinical study begins with healthy participants to [...]
Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
03/12/2025
Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients presenting with 35 different non-classical EGFR mutations; no new safety signals [...]
Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
03/12/2025
Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance (p=0.03 and p=0.04, [...]
Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
03/12/2025
Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a sustained release [...]
Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
03/12/2025
- Type C Meeting with U.S. Food and Drug Administration (FDA) Scheduled for Second Half of January - PURCHASE, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ [...]
GCANRx Announces Relisting To OTCQB Market Tier
03/12/2025
Baltimore, Dec. 03, 2025 (GLOBE NEWSWIRE) -- The Greater Cannabis Company, Inc. (OTC: GCAN) (“the Company”), a clinical stage biopharmaceutical company focused on the development of new and effective cannabinoid [...]
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/12/2025
BRISBANE, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today [...]
Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program
03/12/2025
FDA feedback provides clear framework for Nexalin’s planned U.S. Pilot Study and supports a potential De Novo pathway for the Gen-2 SYNC™ device in Alzheimer’s disease HOUSTON, TX, Dec. 03, 2025 (GLOBE NEWSWIRE) -- [...]
DIMERx Appoints Lee S. Simon, MD as Chief Advisor for Clinical Development & Regulatory Strategy
03/12/2025
Veteran FDA and Industry Leader to Guide Late-Stage Programs, Including First-In-Class Non-Addictive Analgesic DMX-101 SAN FRANCISCO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- DIMERx, Inc. (“DIMERx”), a clinical-stage [...]
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
03/12/2025
MALVERN, Pa., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases [...]
Arrakis Therapeutics Presents Data Highlighting Progress of Oral RNA-targeted Small Molecule to Treat Myotonic Dystrophy Type 1 (DM1)
03/12/2025
Preclinical in vivo data demonstrate hyper-precise mechanism directly targets the disease-causing mRNA repeats leading to correction of splicing defects and reversal of myotonia Oral administration of lead drug [...]
Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum
03/12/2025
Company advances JOTROL ™ into Phase 2a Parkinson’s trial, launches Nugevia ™ consumer brand, and strengthens financial position Jupiter, Florida, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: [...]
Apyx Medical Corporation Announces Approval and Commercial Launch of Apyx One Console and Single-Use Handpieces for Cosmetic Surgical Procedures in South Korea
03/12/2025
Initial commercial orders for the Apyx One console in South Korea are expected in Q4 2025 CLEARWATER, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (Nasdaq: APYX) (the “Company” or “Apyx Medical”) the [...]
March Biosciences Announces Appointment of Gurpreet Ratra, Ph.D., as Chief Business Officer
03/12/2025
Biotech veteran with over 25 years of business development, strategy and operational experience joins March Bio’s management team HOUSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an emerging [...]
Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors
03/12/2025
– Initial clinical data expected mid-2026 – SOUTH SAN FRANCISCO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site- [...]
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
03/12/2025
Initiation of trial marks milestone for Crinetics’ novel nonpeptide drug conjugate platform SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the first patient [...]
Kestra Medical Technologies, Ltd. to Report Second Quarter Fiscal 2026 Financial Results
03/12/2025
KIRKLAND, Wash., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced that it will report second quarter fiscal [...]
Inside information: Orion to receive EUR 180 million milestone and updates full-year outlook for 2025
03/12/2025
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 3 DECEMBER 2025 at 09.00 EET Inside information: Orion to receive EUR 180 million milestone and updates full-year outlook for 2025 Orion Corporation has been [...]
Cession de 9 actifs immobiliers en Belgique
03/12/2025
Communiqué de presse Cession de 9 actifs immobiliers en Belgique Paris, le 3 décembre 2025 Clariane (CLARI.PA – ISIN FR0010386334) : Clariane annonce aujourd’hui la cession d’un portefeuille d’actifs de santé situés en [...]

Pages